Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc. (TSHA) has a dated narrative snapshot, but its priced-in model claim is temporarily suppressed because the model-solve record is unavailable or has changed.
181 institutional managers reported holding TSHA in 13F filings for the quarter ended 2026-03-31. Together they hold about 72% of the company; the top 10 hold 48%. 24 opened new positions that quarter. Held by Goldman Sachs, BlackRock, Morgan Stanley, among others. On the short side, 38.7M shares were sold short as of the 2026-06-15 count, about 11% of shares outstanding (15.4 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
Open-market insider buys at TSHA over the trailing three years: 2023: 6 buys totaling $16.18M; 2024: 1 buy totaling $3.00M; 2025: 1 buy totaling $2.06M. 7 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
TSHA's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-15 | +194.6% | +3.2% |
| 2023-11-15 | +26.3% | -6.0% |
| 2024-03-20 | +39.0% | +0.3% |
| 2024-05-15 | +29.6% | -26.4% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
TSHA's latest 8-K filings: 2026-08-11 (items 2.02, 9.01); 2026-06-25 (items 1.01, 8.01, 9.01); 2026-06-22 (items 7.01, 8.01, 9.01); 2026-06-02 (items 5.07); 2026-05-06 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 11, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.